Supplemental Digital Content: 1 "Table 2"

Table 2 Antiretroviral and cardiovascular drugs exposure among cases and controls

	Control	Case		Control	Case		18 month cIMT missing subgroup
n	99	33	*p*	97	32	*p*	*p*
	Number of patients at the inclusion			Exposure (in days) during the study			
Lamivudine	74	18	*0.04*	352	315	*NS*	*NS*
Emtricitabine∗	0	0	*NS*	48	107	*0.04*	*NS*
Zalcitabine∗	1	0	*NS*	4	0	*NS*	*NS*
Zidovudine	51	4	*<0.001*	268	30	*<0.001*	*<0.001*
Tenofovir	25	14	*0.07*	129	299	*<0.001*	*<0.001*
Stavudine∗	3	1	*NS*	8	25	*NS*	*NS*
Didanosine	10	10	*0.01*	52	192	*<0.001*	*NS*
Abacavir	20	7	*NS*	71	49	*NS*	*NS*
Indinavir∗	1	0	*NS*	0	0	*NS*	*NS*
Lopinavir ∗	17	2	*NS*	87	18	*0.04*	*<0.001*
Fosamprenavir ∗	3	0	*NS*	23	8	*NS*	*NS*
Nelfinavir ∗	2	0	*NS*	12	0	*NS*	*NS*
Atazanavir	0	21	*<0.001*	8.7	483	*<0.001*	*<0.001*
Efavirenz	27	0	*<0.001*	141	0.4	*<0.001*	*0.004*
Nevirapine	22	2	*0.04*	110	44	*NS*	*NS*
Without HAART∗	11	6	*NS*	25	8	*NS*	*NS*
Patients treated by, n	at the inclusion	at the last cIMT					
ß blockers	3	0		4	0		
Calcium antagonists	1	0		2	0		
ACE inhibitors	2	1		2	1		
Fibrates	4	0		5	1		
Statins	6	2		7	2		
Insulin	1	1		1	1		
Biguanids	3	1		3	1		
Sulfamids	2	0		2	0		
Salicylic acid	5	2		4	2		
Anti coagulants	0	0		2	0		

i) Exposure to each antiretroviral drug: number of patients currently exposed at baseline and length of exposure (day) during the study. (The antiretroviral drugs to which none patient was exposed are not showed. All the protease inhibitors were ritonavir boosted.) ii) In the last column: sub-analysis of cases versus controls whose cIMT was not available at 18 months. The statistical analysis is provided only for information. Some samples are too small for khi^2 test (∗). NS: not significant ($p>0.05$).